论文部分内容阅读
目的:研究宫颈癌患者人乳头状瘤病毒(HPV)感染负荷量及血清血管内皮生长因子(VEGF)水平与新辅助化疗效果的相关性,探讨其预测宫颈癌化疗效果的可能性。方法:收集2010年6月至2011年12月云南省肿瘤医院宫颈癌患者40例,均接受新辅助化疗1～3个疗程,化疗结束后3～4周评价治疗效果。化疗前采用二代杂交捕获技术(HC-Ⅱ)检测HPV DNA负荷量,酶联免疫法(ELISA)检测宫颈癌患者血清VEGF水平,分析化疗效果与化疗前HPV负荷量、血清VEGF水平的关系。结果:(1)新辅助化疗临床有效率为85%;(2)宫颈癌患者HPV感染负荷量、血清VEGF水平与新辅助化疗效果呈负相关(P<0.05);(3)HPV感染负荷量与血清VEGF水平呈正相关(R=0.525,P<0.05);(4)HPV病毒负荷量、血清VEGF水平与宫颈癌患者临床病理类型、FIGO分期均无相关性(P>0.05)。结论:宫颈癌新辅助化疗效果明显,联合检测宫颈癌患者HPV病毒负荷量及血清VEGF可以有效预测宫颈癌新辅助化疗效果,该法简单、方便,值得临床推广应用。
Objective: To study the relationship between HPV infection and serum vascular endothelial growth factor (VEGF) level in patients with cervical cancer and the effect of neoadjuvant chemotherapy, and to explore the possibility of predicting the effect of chemotherapy in cervical cancer. Methods: Forty patients with cervical cancer from June 2010 to December 2011 in Yunnan Cancer Hospital were enrolled in this study. All patients underwent neoadjuvant chemotherapy for 1 to 3 courses of chemotherapy. The therapeutic effect was evaluated 3 to 4 weeks after chemotherapy. Before chemotherapy, HPV DNA load was detected by second-generation hybridization capture technique (HC-Ⅱ), serum VEGF level was detected by enzyme-linked immunosorbent assay (ELISA), and the relationship between chemotherapy effect and pre-chemotherapy HPV load and serum VEGF level was analyzed. Results: (1) The clinical effective rate of neoadjuvant chemotherapy was 85%. (2) The HPV infection load and serum VEGF level in cervical cancer patients were negatively correlated with neoadjuvant chemotherapy (P <0.05). (3) (P <0.05). (4) There was no correlation between HPV load and serum VEGF levels and clinical pathological type and FIGO stage (P> 0.05). Conclusion: The effect of neoadjuvant chemotherapy for cervical cancer is obvious. Combined detection of HPV load and serum VEGF in patients with cervical cancer can effectively predict the effect of neoadjuvant chemotherapy for cervical cancer. The method is simple and convenient and worthy of clinical application.